Literature DB >> 15330183

Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer.

Gurpreet Singh Ranger1, Valerie Thomas, Andrew Jewell, Kefah Mokbel.   

Abstract

BACKGROUND: Cyclooxygenase-2 (COX-2) overexpression clearly plays an important role in the pathogenesis of breast cancer. In this study, we analysed the relationship between COX-2 expression and various clinicopathological factors in human breast cancer.
MATERIALS AND METHODS: Using immunohistochemistry, we analysed archival specimens of human breast cancer (n=29) using antibodies to COX-2, ER, PgR and HER2 and, from medical records, obtained clinicopathological data.
RESULTS: We observed a significant association between COX-2 overexpression and distant metastasis. COX-2 expression was not significantly associated with any other clinical or pathological variable.
CONCLUSION: These findings lend support to the hypothesis that COX-2 overexpression represents an adverse prognostic event in human breast cancer and are encouraging for proposed strategies of COX-2 suppression to treat the disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15330183

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  20 in total

Review 1.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

2.  Characterization of a lipid hydroperoxide-derived RNA adduct in rat intestinal epithelial cells.

Authors:  Peijuan Zhu; Seon Hwa Lee; Suzanne Wehrli; Ian A Blair
Journal:  Chem Res Toxicol       Date:  2006-06       Impact factor: 3.739

3.  High expression of TRIM44 is associated with enhanced cell proliferation, migration, invasion, and resistance to doxorubicin in hepatocellular carcinoma.

Authors:  Xinghua Zhu; Yaxun Wu; Xiaobing Miao; Chunsun Li; Haibing Yin; Shuyun Yang; Xiaoyun Lu; Yushan Liu; Yali Chen; Rong Shen; Xudong Chen; Song He
Journal:  Tumour Biol       Date:  2016-09-12

Review 4.  Role of Aspirin in Breast Cancer Survival.

Authors:  Wendy Y Chen; Michelle D Holmes
Journal:  Curr Oncol Rep       Date:  2017-07       Impact factor: 5.075

5.  Cyclooxygenase-2 gene polymorphisms and the risk of colorectal cancer: A population-based study.

Authors:  Hongxia Li; Qinyue Guo; Bo Zhou; Shuixiang He
Journal:  Oncol Lett       Date:  2015-07-09       Impact factor: 2.967

6.  Aspirin intake and survival after breast cancer.

Authors:  Michelle D Holmes; Wendy Y Chen; Lisa Li; Ellen Hertzmark; Donna Spiegelman; Susan E Hankinson
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

7.  Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow.

Authors:  Anthony Lucci; Savitri Krishnamurthy; Balraj Singh; Isabelle Bedrosian; Funda Meric-Bernstam; James Reuben; Kristine Broglio; Kailash Mosalpuria; Ashutosh Lodhi; Laura Vincent; Massimo Cristofanilli
Journal:  Breast Cancer Res Treat       Date:  2008-07-29       Impact factor: 4.872

8.  Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis.

Authors:  Isabella W Cheuk; Vivian Y Shin; Man T Siu; Julia Y Tsang; John C Ho; Jiawei Chen; Gary M Tse; Xian Wang; Ava Kwong
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

9.  Role of LOXs and COX-2 on FAK activation and cell migration induced by linoleic acid in MDA-MB-231 breast cancer cells.

Authors:  Nathalia Serna-Marquez; Socrates Villegas-Comonfort; Octavio Galindo-Hernandez; Napoleon Navarro-Tito; Alejandro Millan; Eduardo Perez Salazar
Journal:  Cell Oncol (Dordr)       Date:  2012-11-21       Impact factor: 6.730

10.  Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.

Authors:  Holger Bronger; Sara Kraeft; Ulrike Schwarz-Boeger; Claudia Cerny; Alexandra Stöckel; Stefanie Avril; Marion Kiechle; Manfred Schmitt
Journal:  Breast Cancer Res       Date:  2012-02-14       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.